Tumor‐derived exosomal miRNA‐320d as a biomarker for metastatic colorectal cancer

Tang, Yulong; Zhao, Yajing; Song, Xingguo; Niu, Limin; Xie, Li

doi:10.1002/jcla.23004

Cited by 78 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in agreement with the results of TEM, that isolated serum exosomes had a spherical morphology with a diameter of 50-150 nm as indicated in Figure 1B. In addition, western immunoblotting con rmed the two well-known protein markers, including CD63 and TSG101 [19,22], which were enriched in exosomes but absent in cell extracts ( Figure 1C). Besides, GM130 as a negative control was only detected in the cell extracts but not in exosomes [20].…”

Section: Identi Cation Of Isolated Serum Exosomessupporting

confidence: 90%

“…Serum biomarkers for diagnosis of NSCLC patients have been widely studied and applied in clinical, such as CEA, CA125, NSE, CYFRA21-1, and CA153 [19,20]. However, there is no any effective biomarker for diagnosis of early-stage NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Given that miRNAs are related to the origination and progression of different diseases such as cancers [10], and are dysregulated in several categories of cancer patients. So exosomal miRNAs can be used as molecular biomarkers for cancer diagnosis [19,20]. For instance, plasma exosomal miR-141-3p and miR-375 were signi cantly over-expressed in rectal cancer patients with synchronous liver metastasis, and can be employed as diagnostic markers of rectal cancer aggressiveness and systemic dissemination [21].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

Zhang¹,

Song²,

Xie

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Abstract Background Exosomal microRNAs (ExmiRNAs) provided a non-invasive and ideal method for cancer diagnosis. However, few studies identified the role of specific serum ExmiRNAs profiles in early non-small cell lung cancer (NSCLC) diagnosis, especially for 0 and I stage. Herein, the present study was designed to validate the novel serum ExmiRNAs as diagnostic biomarkers for early-stage NSCLC. Methods Serum exosomes were collected from the healthy donors and NSCLC patients by ultracentrifugation, and characterized with qNano, TEM, and western immunoblotting. Exosomal RNAs were subjected to miRNA array for evaluating the expression levels of miRNAs. Partly differently expressed serum exosomal miRNAs were verified by large-scale samples from 312 healthy donors and 318 NSCLC patients. Results The expression levels of ExmiR-155-5p and ExmiR-658 were significantly down-regulated in NSCLC patients compared to healthy donors (p < 0.0001 and p < 0.0001, respectively), and they could differentiate NSCLC patients from healthy donors with area under the ROC curve (AUC) of 0.716 and 0.728, respectively. In addition, combination of ExmiR-155-5p and ExmiR-658 could improve the diagnostic capacity with AUC value of 0.781. Moreover, ExmiR-155-5p and ExmiR-658 could differentiate early-stage NSCLC patients (0 and I stage) from healthy donors with AUC values of 0.668 and 0.735, respectively, combination could improve the diagnostic capacity with AUC value of 0.759. Specifically, the expression of ExmiR-155-5p was significantly decreased in patients with lymph node metastasis and distant metastasis (p = 0.0018 and p = 0.0077, respectively). Conclusions Our results identified that serum ExmiR-155-5p and ExmiR-658 were promising diagnostic biomarkers for early-stage NSCLC, and combination of them could improve the diagnostic capacity.

show abstract

Section: Identi Cation Of Isolated Serum Exosomessupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

Zhang¹,

Song²,

Xie

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, miR-320d was found to significantly distinguish patients with metastatic CRC from those who were non-metastatic with a sensitivity of 62% and a specificity of 64.7%. When it was combined with CEA, the sensitivity and specificity rose to 63.3% and 91.3%, respectively [92]. In summary, these miRs could be utilized as potential diagnostic markers of CRC, whereby some are diagnostic of early stages, while others of distant metastatic disease.…”

Section: Diagnostic Biomarkersmentioning

confidence: 94%

Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer

Baassiri

Nassar

Mukherji

et al. 2020

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide, with a high mortality rate, especially in those that are diagnosed in late stages of the disease. The current screening blood-based markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), have low sensitivity and specificity. Meanwhile, other modalities are either expensive or invasive. Therefore, recent research has shifted towards a minimally invasive test, namely, liquid biopsy. Exosomes are favorable molecules sought in blood samples, since they are abundant, stable in circulation, and harbor genetic information and other biomolecules that could serve as biomarkers or even therapeutic targets. Furthermore, exosomal noncoding RNAs, such as miRNAs, lncRNAs, and circRNAs, have demonstrated the diagnostic potential to detect CRC at an early stage with a higher sensitivity and specificity than CEA and CA19-9 alone. Moreover, they have prognostic potential that is TNM stage specific and could serve as predictive biomarkers for the most common chemotherapeutic drug and combination regimen in CRC, which are 5-FU and FOLFOX, respectively. Therefore, in this review, we focus on the role of these exosomal noncoding RNAs as diagnostic, prognostic, and predictive biomarkers. In addition, we discuss the advantages and challenges of exosomes as a liquid biopsy target.

show abstract

“…In CRC, miR-1246 was also found to be significantly increased in CRC tissues, and functioned as a tumor promoting factor through inducing cell proliferation, migration, invasion and chemoresistance 24,25 . Moreover, some specific exosomal microRNAs (miRNAs), including miR-1246, were identified as a biomarker for metastatic colorectal cancer [26][27][28] . In addition, Peng et al demonstrated that miR-1246/SPRED2/MAPK axis played an important role in the progression of CRC 29 .…”

Section: Dusp9 Expression Is Silenced Via Promoter Hypermethylation Inmentioning

confidence: 99%

Downregulation of Dual-specificity phosphatase 9 promotes tumor progression and contributes to poor prognosis in colorectal cancer

Qiu¹,

Liang²,

Sun³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Dual-specificity phosphatase 9 (DUSP9) belongs to the dual-specificity protein phosphatase subfamily. Recently, increasing attention has been paid on the role of DUSP9 in a variety of cancers. However, its functional role in tumor development is still unclear, especially in colorectal cancer (CRC). Methods The functional role of DUSP9 in inhibiting the progression of CRC was verified both in vivo and in vitro using colony formation assay, EdU incorporation assay, wound healing assay, nude mice xenograft model, and et al. RNA-seq was performed to assess the gene expression profiling in SW480 cells with DUSP9 stable knockdown and shControl cells. Bisulfite sequencing (BSE) was performed to reveal methylation status of CpG island in promoter of DUSP9. Results DUSP9 was significantly down regulated in tumor tissues compared with peritumor tissues. Moreover, low DUSP9 expression in CRC was closely associated with tumor size, depth of invasion and advanced TNM stage, indicating that DUSP9 may be involved in the progression of CRC. Kaplan–Meier survival analysis showed that the overall survival (OS) and recurrence-free survival (RFS) of patients with low expression of DUSP9 were significantly shorter than that of patients with high expression of DUSP9. Functional study revealed that DUSP9 inhibited tumor migration, invasion and metastasis both in vitro and in vivo . Mechanistically, low expression of DUSP9 in CRC was caused by the upregulation of miR-1246 and hypermethylation status of CpG island in promoter of DUSP9. Conclusion Our findings demonstrate that DUSP9 plays a critical role in the progression of CRC and therapeutic intervention to increase the expression or activity of DUSP9 may be a potential target for CRC treatment in the future.

show abstract

Tumor‐derived exosomal miRNA‐320d as a biomarker for metastatic colorectal cancer

Cited by 78 publications

References 34 publications

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer

Downregulation of Dual-specificity phosphatase 9 promotes tumor progression and contributes to poor prognosis in colorectal cancer

Contact Info

Product

Resources

About